Navigation Links
Knowledge of genetics improves uncertain medication
Date:2/19/2009

Roughly 100,000 Swedes are under treatment with the blood-thinning drug Waran. Patients evince varying sensitivity to Waran, which makes the initiation of treatment a risky balancing act between hemorrhaging and clotting. Now researchers at Uppsala University have developed a model for calculating the appropriate dose before treatment starts. The study appears in the scientific publication New England Journal of Medicine.

Some 20 research teams in four regions of the world have joined together to study whether it is possible to determine the proper dosage of Waran before starting treatment. Data from 5,700 subjects undergoing treatment with Waran were collected from the four parts of the globe. Niclas Eriksson, a statistician at UCR Uppsala Clinical Research Center has developed a model for calculating the right dosage of Waran for individuals of European, African, and Asian origin.

"The findings show that with the aid of two genes, VKORC1 and CYP2C9, it is possible to predict what dosage patients will land at," says Niclas Eriksson.

"Almost half of patients have mutations that entail that they need a slightly lower dose than normal, and a small percentage need a much lower dose," says Mia Wadelius, a physician and researcher in clinical pharmacology, Uppsala University Hospital, who was in charge of collecting the data in Sweden.

The next step will be to test this method on patients in health care. This spring an American clinical test will get underway to study whether custom-tailored treatment increases the certainty in treating patients with Waran. Similar clinical testing will start this autumn in seven countries in Europe. A total of 3,000 patients who are starting treatment with blood-thinning medicines will be recruited. The Swedish part of the study will be directed by Mia Wadelius, and the Waran clinics in Uppsala and Skne will be participating. Patients will start either with a custom-tailored dosage or with the normal dosage and then be compared.

"Even patients receiving a tailored dose need regular tests of the blood's ability to coagulate, since diet and other medicines play a role, but it is our hope that the treatment will be both safer and more secure with tailored dosage," says Mia Wadelius.


'/>"/>

Contact: Mia Wadelius
Mia.Wadelius@medsci.uu.se
46-018-611-4945
Uppsala University
Source:Eurekalert

Related medicine news :

1. Survey reveals disparities in skin cancer knowledge, protection among high school students
2. Health Knowledge Empowers the Public
3. ER episode impacts viewers health knowledge and behavior
4. ER episode impacts viewers health knowledge and behavior
5. Eclipsys Knowledge-Based Charting Helps Health First Improve Patient-Care Outcomes
6. Americans Knowledge of Fats Growing But Still Insufficient
7. Gauging parent knowledge about teens substance use
8. Education program leads to lasting improvement of cancer knowledge in African Americans
9. HealthTek Software Solutions Licenses First DataBanks OrderView Med Knowledge Base(TM) to Streamline Medication Selection, Management and Reconciliation
10. Education program leads to lasting improvement of cancer knowledge in African-Americans
11. Final of EPSRCs 2007 Knowledge Transfer Challenge Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
Breaking Medicine Technology: